Myriad Genetics, Inc. (NASDAQ:MYGN) has been downgraded to Sell in a statement by Ladenburg Thalmann earlier today.
- Updated: October 10, 2016
Ladenburg Thalmann has downgraded Myriad Genetics, Inc. (NASDAQ:MYGN) to Sell in a statement released on 10/10/2016.
Having a price of $21.34, Myriad Genetics, Inc. (NASDAQ:MYGN) traded -7.10% lower on the day. With the last close down -34.04% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. The company has recorded a 50-day moving average of $20.97 and a 200-day moving average of $30.07. 811,133 shares of MYGN traded hands, down from an average trading volume of 1,773,300
With a total market value of $0, Myriad Genetics, Inc. has price-earnings ratio of 11.60 with a one year low of $19.10 and a one year high of $46.24 .
A total of 12 equity analysts have released a ratings update on MYGN. Four equity analysts rating the company a strong buy, four equity analysts rating the company a buy, seven equity analysts rating the company a hold, three brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $39.58.
General Company Details For Myriad Genetics, Inc. (NASDAQ:MYGN)
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.